Skip to main content
SpringerLink
Log in

Dulaglutide cost effective as add-on T2DM treatment in Italy

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Torre E, et al. Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study. ClinicoEconomics and Outcomes Research : 8 Apr 2020. Available from: URL: https://doi.org/10.2147/CEOR.S240183

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Dulaglutide cost effective as add-on T2DM treatment in Italy. PharmacoEcon Outcomes News 851, 19 (2020). https://doi.org/10.1007/s40274-020-6742-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-020-6742-4

Search

Navigation